28.7 C
Vientiane
Friday, June 20, 2025
spot_img
Home Blog Page 51

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

Significant anti-tumor responses and reduction of brain metastases observed

SEOUL, South Korea , June 2, 2025 /PRNewswire/ — J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world’s largest oncology conference, held in Chicago, USA.

Professor Byoung Chul Cho from Yonsei Cancer Center, posing with the JIN-A02 poster at the ASCO 2025 (Photo=J INTS BIO)
Professor Byoung Chul Cho from Yonsei Cancer Center, posing with the JIN-A02 poster at the ASCO 2025 (Photo=J INTS BIO)

JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented.

‘Confirmed’ clinical response observed in patients with disease progression after 3rd Generation EGFR TKI and chemotherapy

One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity.

In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases.

Safety confirmed up to 300 mg, with therapeutic signals in brain metastases 

No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug’s excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months.

In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue.

JIN-A02 gains national spotlight as government grants accelerate development

In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the ‘2025 Baby Unicorn Fostering Project’ by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The ‘Baby Unicorn Fostering Project’ is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as ‘potential unicorns’. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential.

With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments.

Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA.

“The ASCO presentation of JIN-A02’s ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance,” said Dr. Anna Jo, CEO. “The government’s continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization”

Step Into Adventure: Agoda’s Guide to Asia’s Top Cities to Explore on Foot

SINGAPORE, June 2, 2025 /PRNewswire/ — Digital travel platform Agoda invites travelers to lace up their walking shoes and discover the charm of Asia’s most stroll-worthy cities. From cobblestone streets to scenic riversides, Agoda’s list of Asia’s top cities to explore on foot celebrates destinations where pedestrian-friendly streets, compact layouts, and clusters of attractions make walking the ideal way to experience the local culture.  

Walking through a city is more than just a way to get around. It’s a journey of discovery that engages all five senses. Whether it’s the aroma of street food wafting through the air, the chatter in bustling markets, or the intricate details of historic architecture, exploring on foot allows travelers to experience the rhythm of daily life, discover hidden corners, and fully engage with their surroundings.  

Agoda has rounded up seven destinations across Asia where walking isn’t just an option—it’s the best way to experience the heart and soul of the city: 

1.       Hanoi, Vietnam: A Stroll Through Time in the Old Quarter 

Hanoi’s Old Quarter is a labyrinth of narrow streets brimming with history and culture. French colonial architecture, ancient temples, and vibrant street markets create a dynamic backdrop for exploration. The area’s pedestrian-friendly layout makes it easy to wander and discover local delicacies like Pho and Bánh mì from street vendors. The Old Quarter’s charm lies in its ability to surprise, with hidden cafés, serene pagodas, and bustling markets around every corner. 

2.       Kurashiki, Japan: Canal-Side Serenity in Okayama Prefecture 

Kurashiki’s Bikan Historical Quarter in Okayama Prefecture is a compact, flat area that is a dream come true for those who love leisurely strolls. The picturesque canals lined with weeping willows and traditional white-walled kura (storehouses) create a tranquil atmosphere. Art enthusiasts will appreciate the Ohara Museum of Art, while shoppers can browse handmade crafts. Walking through Kurashiki feels like stepping into a postcard, with every corner offering a picture-perfect view.  

3.       Chiang Khan, Thailand: Riverside Charm in Loei Province 

Nestled along the Mekong River, Chiang Khan is a quaint town located in northeastern Thailand that’s best explored on foot. Its famous pedestrian-friendly walking street, Chai Khong Road, is a car-free stretch lined with well-preserved wooden shophouses, cozy guesthouses, quirky cafés, and local boutiques. In the evenings, it transforms into a lively night market with street food, handicrafts, and live music. Visitors can also experience the serene Buddhist ritual of giving alms to monks at dawn, a photogenic and peaceful tradition. Don’t forget to catch the sunrise over the Mekong for a truly magical experience. 

4.      Melaka, Malaysia: A Fusion of Cultures in a UNESCO-Listed Old Town 

Melaka Old Town is a UNESCO World Heritage site that’s compact, flat, and ideal for a walking tour. The city’s rich history as a trading port is reflected in its diverse architecture, from Dutch colonial buildings to Chinese shophouses. Attractions, museums, cafés, and shops are clustered together, making it easy to wander on foot. Jonker Street and the surrounding heritage area are car-free on weekends, ensuring a safe and enjoyable walking experience. Shaded walkways, riverside promenades, and historical sites add to the charm of this culturally rich destination. 

5.       Pondicherry, India: A French Connection  

Pondicherry’s French Quarter is a walker’s paradise, with its grid-like street layout, pastel-colored colonial buildings, and tree-lined avenues. The seaside promenade, Goubert Avenue, is closed to vehicles in the evenings and early mornings, offering a peaceful space for pedestrians to stroll or relax by the sea with views of the Bay of Bengal. The city’s relaxed vibe, with less traffic and noise compared to many Indian cities, makes it an ideal destination for those who enjoy exploring on foot. 

6.       Gyeongju, South Korea: A Walk Through History 

Known as “the museum without walls,” Gyeongju’s historic city center is a treasure trove of historical sites, making it perfect for walking. The main attractions, including Tumuli Park, Cheomseongdae Observatory, Gyeongju National Museum, and Woljeonggyo Bridge, are all within walking distance of each other. The city’s well-maintained sidewalks, pedestrian zones, and scenic walking paths make it easy to explore on foot at a leisurely pace.  

7.       Taipei, Taiwan: The Emerging “15-Minute City” 

Cited by The Economist as an emerging “15-minute city,” Taipei offers wide sidewalks, clear signage, and shaded boulevards for the perfect city adventure, complete with an efficient MRT system that connects walkable hubs seamlessly. Highlights include Da’an Forest Park, Yongkang Street’s food scene, the historic Dihua Street in Dadaocheng, and the Songshan Cultural and Creative Park loop. Scenic riverside bikeways and walkways add another layer of accessibility and beauty to the city. 

Andrew Smith, Senior Vice President, Supply at Agoda, shared, “Walking is such a simple yet rewarding way to explore a destination. It’s about letting the world unfurl around you, noticing the little things, and really soaking in the atmosphere of a place. At Agoda, we love to help travelers find places where they can wander, get lost, and make memories that last a lifetime. Whether you’re strolling through Hanoi’s Old Quarter or catching the sunrise in Chiang Khan, we’ve got the stays and activities to make your trip unforgettable.” 

With Agoda’s extensive offerings of over 5 million holiday properties, 130,000 flight routes, and 300,000 activities, travelers can easily plan their next walking adventure. Visit Agoda.com or download the Agoda mobile app for the best deals and seamless booking options. 

— ENDS —

PingPong Expands Leading B2B Cross-Border Payments Platform Into Malaysia, Further Unlocking South East Asia For Enterprise Clients

  • PingPong has been granted a Money Services Business Licence Class B, from Malaysia’s central bank, Bank Negara Malaysia, unlocking a USD $445 billion economy for enterprises, financial institutions, and SaaS companies expanding into and out of Malaysia.
  • This follows PingPong’s recent expansion into Indonesia and existing presence in Vietnam, Thailand, Singapore and the Philippines, further expanding PingPong’s comprehensive portfolio of over 60 global licences.

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 2 June 2025 – PingPong, the world-leading provider of cross-border embedded payment solutions for enterprises, is pleased to announce that it has been granted a Money Services Business Licence from Malaysia’s central bank, Bank Negara Malaysia. This latest licence further adds to PingPong’s extensive portfolio of over 60 global licences, unlocking even more cross-border opportunities for enterprises on PingPong’s platform.

Malaysia offers significant growth opportunities for enterprises looking to scale in Southeast Asia. Its GDP is expected to reach $445 billion USD by the end of 2025 and grow by 33% by 2030, reaching $600 billion USD. International trade is a significant part of Malaysia’s wealth, valued at 132% of GDP in 2023.

Financial services and fintechs are thriving across Southeast Asia, with Malaysia emerging as a key player. The country ranks third in the region in terms of the number of fintech companies it has, and it is poised for significant growth. Malaysia’s fintech sector is projected to double, from $54 billion USD in 2025 to $111 billion USD by 2030, reflecting a robust compound annual growth rate (CAGR) of 16%. Its strategic location, high digital adoption rate, and robust financial sector have made it one of the key growing countries in Southeast Asia.

Jianqin Shu, Partner and APAC General Manager at PingPong, said, “As one of the most strategically positioned and rapidly growing economies in Southeast Asia, Malaysia presents an incredible opportunity for enterprises scaling their global operations. Securing a Money Services Business licence positions PingPong at the heart of this growth, empowering us to support Malaysia’s expanding fintech and financial services ecosystem, meeting the rising demand for efficient, compliant cross-border payment solutions. This milestone enables us to extend our global reach further and provide enterprises with end-to-end, one-stop payment services.”

This approval adds to PingPong’s already significant portfolio of over 60 global licences across the United States, EU, UK, Hong Kong, mainland China, Canada, Australia, Japan, Singapore, Indonesia and other countries and regions worldwide.
Hashtag: #PingPong

The issuer is solely responsible for the content of this announcement.

About PingPong

was founded in New York in 2015, with the goal of solving the immense challenge of scaling enterprise businesses globally. Fast forward to today, and PingPong has become one of the world’s leading global cross-border payments platforms, processing more than $250 billion USD. Our API-first cross-border payments platform integrates with enterprises to send, manage, and receive money faster on a global scale.

PingPong currently has 37 offices in 15 countries and 1,500 employees. Our international presence helps businesses solve complex payment needs in every major economy across all time zones.

Press contact: press@international.pingpongx.com

June 2025 Market Outlook: Essential Economic and Geopolitical Events for Traders by Octa Broker


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 2 June 2025 – June 2025 is shaping up to be one of the most eventful months of the year for global markets. For traders, this means opportunity—but also volatility. The economic calendar is packed with macroeconomic data releases and central bank meetings, while geopolitical risks remain close to the surface.

Octa Broker

Beyond the usual inflation prints and interest rate decisions, markets will also have to digest key developments around global diplomacy: the NATO and G7 summits, peace negotiations in Eastern Europe, U.S. trade talks with China and the European Union, as well as debates around nuclear policy in the Middle East. Add to this the lingering fiscal tensions in Washington, and it’s clear that June won’t be business as usual. Octa Broker explains why the economic calendar is worth monitoring and what events to watch out for in June 2025.

The Role of the Economic Calendar for Traders

For traders, the economic calendar is more than a schedule—it’s a risk map. It flags:

  • central bank rate decisions
  • inflation and employment reports
  • Gross Domestic Product (GDP) estimates and growth outlooks
  • high-level summits with potential for market-moving headlines.

These events affect not just macro sentiment but also short-term liquidity and intraday volatility. And when several collide—as they will in June—market reactions tend to be sharper, faster, and harder to fade. Anticipating such events in advance allows traders to capitalise on potential opportunities and adjust risk management—some even avoid trading during volatility.

Key Economic Events in June 2025

Here are some major events to follow in June:

  • June 4: Bank of Canada (BoC) interest rate decision
  • June 5: European Central Bank (ECB) rate decision
  • June 6: U.S. Non-Farm Payrolls
  • June 11: U.S. Consumer Price Index (CPI)
  • June 15–17: Group-7 (G7) Summit
  • June 17: Bank of Japan (BoJ) rate decision
  • June 18: Federal Reserve (Fed) rate decision—includes Economic Projections and the Dot Plot
  • June 19: Swiss National Bank (SNB) rate decision
  • June 19: Bank of England (BoE) rate decision
  • June 20: People’s Bank of China (PBoC) rate decision
  • June 24–25: North Atlantic Treaty Organisation (NATO) Summit
  • June 26–27: European Council Summit
  • June 27: U.S. Personal Consumption Expenditure (PCE) Price Index
  • June 30: German CPI

Potential Impact of June Economic and Geopolitical Events For Traders
Heightened Volatility Expected

June is shaping up to be an eventful month for currencies and rate-sensitive assets, with seven major central bank meetings scheduled—the BoC, BoE, BoJ, ECB, Fed, SNB, and PBoC. Traders can anticipate heightened volatility not only in the major USD-based pairs but also in equity indices, individual stocks, and commodities.

June’s Federal Reserve meeting is particularly important, accompanied by updated Economic Projections and the Dot Plot—forward-looking instruments via which markets infer future rate trajectories. Surprises can unleash dramatic repricing in Treasury yields, gold, and risk assets.

Macroeconomic Divergence as a Market Driver

Inflation paths remain divergent. In the U.S., core CPI slowed to 2.3% YoY, potentially softening the Fed’s stance. Meanwhile, ECB officials appear divided: Klaas Knot said inflation risks remain uncertain, while Pierre Wunsch hinted that rates could fall below 2%. This split supports tactical positioning in EUR/USD and EUR/GBP, particularly around central bank commentary.

Geopolitical Events Could Disrupt Risk Sentiment

June’s summits aren’t ceremonial. The G7 Summit will cover trade security and energy cooperation, while the NATO meeting will focus on defence spending and alliance posture. Any hawkish statements or surprises around Ukraine, China, or the Middle East could move commodity markets—particularly, oil and gold—and affect defence-sector equities.

Bond Market Tensions Could Spill Into FX and Equities

Rising Treasury yields, recently breaching 5.0% on 20-year note, are fueling concern over U.S. fiscal policy. As Moody’s warned, the sustainability of U.S. debt is becoming a market risk. Traders should watch for safe-haven rotation into gold, Bitcoin, Swiss franc (CHF), and the Japanese yen (JPY). Japan, however, is facing debt troubles of its own, as yields on 30-year bonds recently climbed to multi-decade highs, prompting calls to BoJ to either increase bond buying or halt its plans to gradually reduce such purchases. Either way, traders should keep a close eye on both the U.S. and the Japanese bond markets.

Ongoing Trade Negotiations Remain a Wildcard

The May U.S.-China joint statement hinted at easing tensions—but markets remain sceptical.

There are still several critical obstacles to a comprehensive trade agreement between the parties. For example, on May 12th, China’s Ministry of Commerce strengthened control over strategic mineral exports, on which the U.S. is highly dependent. Other critical sticking points include technology transfer issues and Artificial Intelligence (AI), as China’s growing semiconductor self-sufficiency efforts are not particularly favoured in Washington. Furthermore, there is still uncertainty as to whether any meaningful progress in trade talks between the U.S. and EU can be achieved in June. Although the parties agreed to fast-track the negotiations, some business leaders are sceptical.

June won’t be a month for passive positioning. With central banks sending mixed signals, inflation data diverging, and global diplomacy back on the front pages, traders will have to juggle more than just charts.

This is the kind of environment where preparation matters more than prediction. Knowing when the Fed drops its Dot Plot is as important as watching where oil prices go after a NATO statement. With overlapping narratives and rising volatility, it’s not about calling the top or bottom—it’s about managing risk around known catalysts and staying nimble when the unknowns hit.

Disclaimer: This content is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to engage in any investment activity. It does not take into account your investment objectives, financial situation, or individual needs. Any action you take based on this content is at your sole discretion and risk. Octa and its affiliates accept no liability for any losses or consequences resulting from reliance on this material.
Trading involves risks and may not be suitable for all investors. Use your expertise wisely and evaluate all associated risks before making an investment decision. Past performance is not a reliable indicator of future results.
Availability of products and services may vary by jurisdiction. Please ensure compliance with your local laws before accessing them.
Hashtag: #octa

The issuer is solely responsible for the content of this announcement.

Octa

is an international CFD broker that has been providing online trading services worldwide since 2011. It offers commission-free access to financial markets and various services used by clients from 180 countries who have opened more than 52 million trading accounts. To help its clients reach their investment goals, Octa offers free educational webinars, articles, and analytical tools.

The company is involved in a comprehensive network of charitable and humanitarian initiatives, including improving educational infrastructure and funding short-notice relief projects to support local communities.

In Southeast Asia, Octa received the ‘Best Trading Platform Malaysia 2024’ and the ‘Most Reliable Broker Asia 2023’ awards from Brands and Business Magazine and International Global Forex Awards, respectively.

Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience

New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials 

SINGAPORE, June 2, 2025 /PRNewswire/ — Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Protocol Optimization, part of the Medidata Study Experience which is available on the Medidata Platform. Medidata is showcasing this novel solution at the American Society of Clinical Oncology (ASCO) 2025 conference, which will be held from May 30–June 3, 2025 in Chicago.

Medidata Protocol Optimization, a flagship component of the unified Study Experience, transforms trial design and execution by leveraging AI-driven predictive modeling, digital protocols, and industry-leading aggregated data to simulate trial performance. This solution has the ability to predict the impact on patient burden, site performance, and costs, well in advance of the First Patient In (FPI) resulting in research teams gaining critical foresight into the potential challenges. This approach significantly decreases costly amendments and enrollment delays, leading to smoother and lower cost trials.

“Oncology trials are some of the most intricate and demanding in clinical research, often leading to more changes during the study than any other therapeutic area,” said Dan Braga, senior vice president, Study Experience, Medidata. “Because of this complexity, we wanted to introduce Protocol Optimization at ASCO to give researchers a deeper look into how balancing scientific intention and practical execution can bring treatments to the market more effectively.”

To learn more about Protocol Optimization, please visit here.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens.  With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact.  For more information, visit: www.3ds.com.

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ — ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics.  
This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies. 

Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161.  
The collaboration combines ASP Isotopes’ expertise in large-scale isotope enrichment—previously demonstrated through its production of Ytterbium-176 (Yb-176)—with Isotopia’s proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years. 

Paul Mann, CEO  of ASP Isotopes, emphasized the agreement’s significance: “By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry’s growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms.” 

Dr. Eli Shalom, CEO of Isotopia, highlighted Tb-161’s therapeutic advantages: “Tb-161’s dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization. We produce in our site in Israel and shortly the production will start in our second site in Indianapolis in the US.” 

Tb-161’s Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-emitting isotopes. This precision aligns with the oncology field’s shift toward targeted radiotherapeutics, which improve efficacy and reduce side effects. The agreement comes as global interest in radiopharmaceuticals surges, driven by their ability to deliver localized radiation therapy via tumor-seeking molecules. 

About ASP Isotopes Inc. 
ASP Isotopes Inc. specializes in advanced isotope separation technologies, including its proprietary Aerodynamic Separation Process and Quantum Enrichment, which produce stable isotopes without radioactive waste. The company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company has isotope enrichment facilities in Pretoria, South Africa. For more information, please visit www.aspisotopes.com.

About Isotopia Molecular Imaging Ltd. 
Isotopia is a global leader in medical isotope production, with facilities in Israel, Europe, and the U.S. Its integrated platform includes cyclotrons, Lu-177 and Tb-161 production sites, and sterile manufacturing capabilities. The company collaborates with researchers and clinicians to develop novel radiopharmaceuticals for diagnostics and targeted therapy. 

This partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide. 

Contact: eshalom@isotopia-global.com 

EnGenius Showcases Smarter AI and Cloud Networking Solutions at Interop Tokyo 2025

Cloud-Managed Wi-Fi 7 and AI Surveillance Solutions That Drive Innovation in Education, Hospitality, and Healthcare

TOKYO, June 2, 2025 /PRNewswire/ — EnGenius Networks Japan, the Japanese subsidiary of global cloud networking leader EnGenius Technologies, will exhibit its latest cloud-managed Wi-Fi 7 and AI surveillance solutions at Interop Tokyo 2025, taking place from June 11 to 13 at Makuhari Messe. Designed to drive digital transformation across education, hospitality, and healthcare sectors in Japan, these innovations deliver secure, high-performance, and easy-to-manage networking environments through cloud and AI integration.

EnGenius Interop booth mockup
EnGenius Interop booth mockup

Highlight Solutions to Show

As part of its comprehensive cloud-managed network ecosystem, EnGenius will introduce its latest Wi-Fi 7 solutions,  featuring ultra-fast performance up to 19 Gbps with 6 GHz band support, multi-link operation (MLO), and 4K QAM, and the sleek in-wall access point to deliver a space-saving, high-performance solution for high-density residential environments such as multiple dwelling units.

EnGenius will also present its contextual AI surveillance solution, which integrates edge computing and cloud-based AI to deliver real-time detection of people, objects, colors, and behaviors, such as walking, stopping, sitting, and picking up items. This technology enhances safety, efficiency, and user experience across a wide range of industries, including elder care, healthcare, retail, agriculture, and manufacturing.

“Our AI cameras are more than surveillance devices; instead, they are the core driver of operational efficiency and new value creation,” said Seiichiro Sato, General Manager of EnGenius Networks Japan. “From retail stores and care facilities to agriculture, fisheries, and manufacturing, our contextual AI recognition delivers real-time insights into the flow of people and objects. This enables businesses to improve productivity, streamline operations, enhance customer satisfaction, and ensure safety and stability across diverse industries.”

A key highlight of this year’s exhibition is EnGenius’s collaboration with NEC Networks & System Integration Corporation, the system integration arm of the NEC Group. By integrating Cloudbrink access, provided by NESIC, into the EnGenius Gateway series, this zero-trust networking solution offers secure, scalable, and high-performance connectivity tailored for Japanese enterprises and GIGA school initiatives.

Key Technologies

  • Advanced Wi-Fi 7 Connectivity
    Delivers next-generation wireless performance with up to 19 Gbps throughput, 6 GHz band support, and multi-link operation (MLO) for seamless, high-speed networking.
  • Contextual AI Recognition Uses large-scale multimodal modeling (LMM) techniques to detect complex scenarios, including suspicious behavior, potential security threats, and public safety events.
  • Natural Language Search of Surveillance
    Enables intuitive, multilingual queries, dramatically reducing search times for specific events in video footage.
  • AI-Network Video System (AI-NVS)
    A cloud-based solution that adds advanced AI analytics to existing ONVIF-compatible cameras and provides RAID-supported enterprise storage for secure, scalable video management.
  • Zero-Trust Network Access
    EnGenius Gateways integrate Cloudbrink services to establish secure, encrypted connections between edge devices, enterprise resources, and public cloud applications, enhancing both the security and performance of remote access.

Event Details

  • Event: Interop Tokyo 2025
  • Date: June 11–13, 2025, 10:00~18:00
  • Location: Makuhari Messe, Booth #5U24
  • Demo Reservation: Attendees who book a demo will receive a limited edition EnGenius Fisherman’s Net Bag. Book here

About EnGenius

EnGenius Technologies is a global leader in cloud-driven networking solutions, with over 25 years of expertise in developing and delivering innovative, user-friendly hardware and software. The company’s secure, cloud-managed ecosystem—including wireless access points, network switches, VPN routers, AI cameras, AI-powered network video systems, and power distribution units—empowers businesses across industries such as enterprise, education, healthcare, retail, and logistics to build high-performance, reliable, and scalable network infrastructures.

For more information, please visit the EnGenius website:  https://www..engeniustech.com/jp/interop-tokyo-2025

Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience

New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials

SINGAPORE, June 2, 2025 /PRNewswire/ — Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Protocol Optimization, part of the Medidata Study Experience which is available on the Medidata Platform. Medidata is showcasing this novel solution at the American Society of Clinical Oncology (ASCO) 2025 conference, which will be held from May 30–June 3, 2025 in Chicago.

Medidata Protocol Optimization, a flagship component of the unified Study Experience, transforms trial design and execution by leveraging AI-driven predictive modeling, digital protocols, and industry-leading aggregated data to simulate trial performance. This solution has the ability to predict the impact on patient burden, site performance, and costs, well in advance of the First Patient In (FPI) resulting in research teams gaining critical foresight into the potential challenges. This approach significantly decreases costly amendments and enrollment delays, leading to smoother and lower cost trials.

“Oncology trials are some of the most intricate and demanding in clinical research, often leading to more changes during the study than any other therapeutic area,” said Dan Braga, senior vice president, Study Experience, Medidata. “Because of this complexity, we wanted to introduce Protocol Optimization at ASCO to give researchers a deeper look into how balancing scientific intention and practical execution can bring treatments to the market more effectively.”

To learn more about Protocol Optimization, please visit here.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens.  With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact.  For more information, visit: www.3ds.com.

Logo – https://laotiantimes.com/wp-content/uploads/2025/06/medidata_logo-1.jpg